Medication before and during pregnancy in anti-Ro/SSA-positive women.
| CHB pregnancy, % (frequency) | Non-CHB pregnancy, % (frequency) | |
| Before pregnancy* | 19 (15/80) | 13 (13/103) |
| Acetylsalicylic acid | 4 (3/80) | 5 (5/103) |
| Hydroxychloroquine | 6 (5/80) | 3 (3/103) |
| Steroids (prednisolone) | 5 (4/80) | 3 (3/103) |
| DMARDs† | 1 (1/80) | 1 (1/103) |
| Levotyroxin | 3 (2/80) | 1 (1/103) |
| During pregnancy‡ | 15 (12/80) | 11 (11/103) |
| Acetylsalicylic acid | 3 (2/80) | 4 (4/103) |
| Hydroxychloroquine | 1 (1/80) | 2 (2/103) |
| Steroids (prednisolone) | 8 (6/80) | 4 (4/103) |
| DMARDs† | 1 (1/80) | 0 (0/103) |
| Levotyroxin | 3 (2/80) | 0 (0/103) |
| Intravenous immunoglobulin | 0 (0/80) | 1 (1/103) |
*Within 3 months before pregnancy and up until week 25 of gestation.
† Disease-modifying antirheumatic drugs (DMARDs): azathioprine and cyclosporine.
‡ Until gestational week 25. No comparisons between CHB and non-CHB groups were significant (p>0.05).